Drug intelligence / Profile preview

olomorasib

Development stage: Phase 3
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

Olomorasib is a selective, covalent inhibitor of the KRAS G12C protein, developed by Eli Lilly and Company. It is used for treating cancers such as non-small cell lung cancer (NSCLC) and colorectal cancer. Olomorasib targets the KRAS G12C mutation, inhibiting mutant KRAS-dependent signaling.

Other names: 2-amino-4-[(4as)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1h,12h-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-benzo[b]thiophene-3-carbonitrile

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on olomorasib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olomorasib.

Explore the full profile